An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population.
<h4>Background</h4>The benefit of using serological assays based on HEV genotype 3 in industrialised settings is unclear. We compared the performance of serological kits based on antigens from different HEV genotypes.<h4>Methods</h4>Taking 20 serum samples from patients in so...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1b1d81a8c78147b5ba703475c6b22b51 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1b1d81a8c78147b5ba703475c6b22b51 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1b1d81a8c78147b5ba703475c6b22b512021-11-18T07:46:37ZAn analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population.1932-620310.1371/journal.pone.0062980https://doaj.org/article/1b1d81a8c78147b5ba703475c6b22b512013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23667554/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The benefit of using serological assays based on HEV genotype 3 in industrialised settings is unclear. We compared the performance of serological kits based on antigens from different HEV genotypes.<h4>Methods</h4>Taking 20 serum samples from patients in southwest France with acute HEV infection (positive PCR for HEV genotype 3) and 550 anonymised samples from blood donors in southwest Switzerland, we tested for anti-HEV IgG using three enzyme immunoassays (EIAs) (MP Diagnostics, Dia.Pro and Fortress) based on genotype 1 and 2 antigens, and one immunodot assay (Mikrogen Diagnostik recomLine HEV IgG/IgM) based on genotype 1 and 3 antigens.<h4>Results</h4>All acute HEV samples and 124/550 blood donor samples were positive with ≥1 assay. Of PCR-confirmed patient samples, 45%, 65%, 95% and 55% were positive with MP Diagnostics, Dia.Pro, Fortress and recomLine, respectively. Of blood donor samples positive with ≥1 assay, 120/124 (97%), were positive with Fortress, 19/124 (15%) were positive with all EIAs and 51/124 (41%) were positive with recomLine. Of 11/20 patient samples positive with recomLine, stronger reactivity for HEV genotype 3 was observed in 1/11(9%), and equal reactivity for both genotypes in 5/11 (45.5%).<h4>Conclusions</h4>Although recomLine contains HEV genotype 3, it has lower sensitivity than Fortress in acute HEV infection and fails to identify infection as being due to this genotype in approximately 45% of patients. In our single blood donor population, we observe wide variations in measured seroprevalence, from 4.2% to 21.8%, depending on the assay used.Annatina SchneggPhilippe BürgisserCyril AndréAlain Kenfak-FoguenaGiorgia CanelliniDarius MoradpourFlorence AbravanelJacques IzopetMatthias CavassiniKatharine E A DarlingPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e62980 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Annatina Schnegg Philippe Bürgisser Cyril André Alain Kenfak-Foguena Giorgia Canellini Darius Moradpour Florence Abravanel Jacques Izopet Matthias Cavassini Katharine E A Darling An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. |
| description |
<h4>Background</h4>The benefit of using serological assays based on HEV genotype 3 in industrialised settings is unclear. We compared the performance of serological kits based on antigens from different HEV genotypes.<h4>Methods</h4>Taking 20 serum samples from patients in southwest France with acute HEV infection (positive PCR for HEV genotype 3) and 550 anonymised samples from blood donors in southwest Switzerland, we tested for anti-HEV IgG using three enzyme immunoassays (EIAs) (MP Diagnostics, Dia.Pro and Fortress) based on genotype 1 and 2 antigens, and one immunodot assay (Mikrogen Diagnostik recomLine HEV IgG/IgM) based on genotype 1 and 3 antigens.<h4>Results</h4>All acute HEV samples and 124/550 blood donor samples were positive with ≥1 assay. Of PCR-confirmed patient samples, 45%, 65%, 95% and 55% were positive with MP Diagnostics, Dia.Pro, Fortress and recomLine, respectively. Of blood donor samples positive with ≥1 assay, 120/124 (97%), were positive with Fortress, 19/124 (15%) were positive with all EIAs and 51/124 (41%) were positive with recomLine. Of 11/20 patient samples positive with recomLine, stronger reactivity for HEV genotype 3 was observed in 1/11(9%), and equal reactivity for both genotypes in 5/11 (45.5%).<h4>Conclusions</h4>Although recomLine contains HEV genotype 3, it has lower sensitivity than Fortress in acute HEV infection and fails to identify infection as being due to this genotype in approximately 45% of patients. In our single blood donor population, we observe wide variations in measured seroprevalence, from 4.2% to 21.8%, depending on the assay used. |
| format |
article |
| author |
Annatina Schnegg Philippe Bürgisser Cyril André Alain Kenfak-Foguena Giorgia Canellini Darius Moradpour Florence Abravanel Jacques Izopet Matthias Cavassini Katharine E A Darling |
| author_facet |
Annatina Schnegg Philippe Bürgisser Cyril André Alain Kenfak-Foguena Giorgia Canellini Darius Moradpour Florence Abravanel Jacques Izopet Matthias Cavassini Katharine E A Darling |
| author_sort |
Annatina Schnegg |
| title |
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. |
| title_short |
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. |
| title_full |
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. |
| title_fullStr |
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. |
| title_full_unstemmed |
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. |
| title_sort |
analysis of the benefit of using hev genotype 3 antigens in detecting anti-hev igg in a european population. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/1b1d81a8c78147b5ba703475c6b22b51 |
| work_keys_str_mv |
AT annatinaschnegg ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT philippeburgisser ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT cyrilandre ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT alainkenfakfoguena ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT giorgiacanellini ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT dariusmoradpour ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT florenceabravanel ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT jacquesizopet ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT matthiascavassini ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT katharineeadarling ananalysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT annatinaschnegg analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT philippeburgisser analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT cyrilandre analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT alainkenfakfoguena analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT giorgiacanellini analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT dariusmoradpour analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT florenceabravanel analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT jacquesizopet analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT matthiascavassini analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation AT katharineeadarling analysisofthebenefitofusinghevgenotype3antigensindetectingantihevigginaeuropeanpopulation |
| _version_ |
1718422957957578752 |